Ross A Soo

Author PubWeight™ 0.92^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?	Front Oncol	2014	0.92